以哈利法克斯为基础的MedMira与圣迈克尔医院合作,在国际人权中心的资助下,开始全面临床试验,以进行梅毒综合测试。 Halifax-based MedMira begins full clinical trials for its comprehensive syphilis test in partnership with St. Michael's Hospital and funded by CIHR.

设在哈利法克斯的一家公司MedMira公司准备进行全面临床试验,以进行它的Multiplo 完整梅毒(TP/nTP)抗体测试。 MedMira Inc., a Halifax-based company, is set to conduct full clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test. 这一快速的关口检查结合了一次高质量的检查和确认,为检测梅毒活性感染提供了全面解决办法。 This rapid point-of-care (POC) test combines screening and confirmation in a single high-quality test, providing a comprehensive solution for detecting active syphilis infections. 这些试验是与圣迈克尔医院城市保健解决方案MAP中心REACH Nexus合作在加拿大卫生研究所的资助下进行的,目的是解决对梅毒感染进行灵活、准确和符合成本效益的检测这一日益增长的需求。 The trials, in partnership with REACH Nexus at St. Michael's Hospital's MAP Centre for Urban Health Solutions and funded by the Canadian Institute of Health Research (CIHR), aim to address the increasing need for flexible, accurate, and cost-effective detection of syphilis infections.